Info
HBV prophylaxis in chemotherapy
- moderate risk: HBsAg-positive individuals receieved cytotoxic chemotherapy
- confirm HBV/HCV profiles prior to administering preventive anti-viral agents for HBV flare-up prophylaxis during chemotherapy.
- start entecavir concurrently or prior to initiating chemotherapy
- maintained for at least 6 months after withdrawal of immunosuppression
- duration of chemotherapy:
___/___/___to___/___/___(estimated) - explain adverse effects:
- headache, fatigue, dizziness, nausea reported in 22% of patients.
- monitor if HBV reactivation:
- previously had undetectable HBV DNA → detectable HBV DNA
- 10x to 100x fold increase in HBV DNA
- HBsAg negative/anti-HBc positive becomes HBsAg positive